OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Islatravir Is Not Expected to Be a Victim or Perpetrator of Drug-Drug Interactions via Major Drug-Metabolizing Enzymes or Transporters
Kelly Bleasby, Robert Houle, Michael J. Hafey, et al.
Viruses (2021) Vol. 13, Iss. 8, pp. 1566-1566
Open Access | Times Cited: 22
Kelly Bleasby, Robert Houle, Michael J. Hafey, et al.
Viruses (2021) Vol. 13, Iss. 8, pp. 1566-1566
Open Access | Times Cited: 22
Showing 22 citing articles:
Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on antiretroviral therapy: 48-week results of a phase 3, randomised, open-label, non-inferiority trial
Jean‐Michel Molina, Giuliano Rizzardini, Catherine Orrell, et al.
The Lancet HIV (2024) Vol. 11, Iss. 6, pp. e369-e379
Closed Access | Times Cited: 7
Jean‐Michel Molina, Giuliano Rizzardini, Catherine Orrell, et al.
The Lancet HIV (2024) Vol. 11, Iss. 6, pp. e369-e379
Closed Access | Times Cited: 7
Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial
Anthony Mills, Giuliano Rizzardini, Moti Ramgopal, et al.
The Lancet HIV (2024) Vol. 11, Iss. 6, pp. e357-e368
Closed Access | Times Cited: 6
Anthony Mills, Giuliano Rizzardini, Moti Ramgopal, et al.
The Lancet HIV (2024) Vol. 11, Iss. 6, pp. e357-e368
Closed Access | Times Cited: 6
Nonclinical and clinical characterization of the absorption, metabolism, and excretion of islatravir
Kerry L. Fillgrove, Randolph P. Matthews, Bing Lu, et al.
Antimicrobial Agents and Chemotherapy (2025)
Open Access
Kerry L. Fillgrove, Randolph P. Matthews, Bing Lu, et al.
Antimicrobial Agents and Chemotherapy (2025)
Open Access
Pharmacokinetics of islatravir in participants with moderate hepatic impairment
Randolph P. Matthews, Munjal Patel, Wen Liu, et al.
Antimicrobial Agents and Chemotherapy (2025)
Open Access
Randolph P. Matthews, Munjal Patel, Wen Liu, et al.
Antimicrobial Agents and Chemotherapy (2025)
Open Access
Diuretic resistance in patients with kidney disease: Challenges and opportunities
Luxuan Guo, Baohui Fu, Yang Liu, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 157, pp. 114058-114058
Open Access | Times Cited: 16
Luxuan Guo, Baohui Fu, Yang Liu, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 157, pp. 114058-114058
Open Access | Times Cited: 16
Current status of the small molecule anti-HIV drugs in the pipeline or recently approved
T. Umumararungu, Jean Baptiste Nyandwi, Jonathan Katandula, et al.
Bioorganic & Medicinal Chemistry (2024) Vol. 111, pp. 117860-117860
Closed Access | Times Cited: 3
T. Umumararungu, Jean Baptiste Nyandwi, Jonathan Katandula, et al.
Bioorganic & Medicinal Chemistry (2024) Vol. 111, pp. 117860-117860
Closed Access | Times Cited: 3
Intracellular islatravir-triphosphate half-life supports extended dosing intervals
Xiaowei Zang, Wendy Ankrom, Walter K. Kraft, et al.
Antimicrobial Agents and Chemotherapy (2024) Vol. 68, Iss. 9
Open Access | Times Cited: 2
Xiaowei Zang, Wendy Ankrom, Walter K. Kraft, et al.
Antimicrobial Agents and Chemotherapy (2024) Vol. 68, Iss. 9
Open Access | Times Cited: 2
Role of islatravir in HIV treatment and prevention: an update
Abdallah Derbalah, Hayley Christine Karpick, Holly Maize, et al.
Current Opinion in HIV and AIDS (2022) Vol. 17, Iss. 4, pp. 240-246
Closed Access | Times Cited: 11
Abdallah Derbalah, Hayley Christine Karpick, Holly Maize, et al.
Current Opinion in HIV and AIDS (2022) Vol. 17, Iss. 4, pp. 240-246
Closed Access | Times Cited: 11
Safety and Pharmacokinetics of Islatravir in Individuals with Severe Renal Insufficiency
Randolph P. Matthews, Youfang Cao, Munjal Patel, et al.
Antimicrobial Agents and Chemotherapy (2022) Vol. 66, Iss. 12
Open Access | Times Cited: 10
Randolph P. Matthews, Youfang Cao, Munjal Patel, et al.
Antimicrobial Agents and Chemotherapy (2022) Vol. 66, Iss. 12
Open Access | Times Cited: 10
Long-Acting Injectable Antiretroviral Agents for HIV Treatment and Prevention
Kim Ys
Infection and Chemotherapy (2021) Vol. 53, Iss. 4, pp. 686-686
Open Access | Times Cited: 12
Kim Ys
Infection and Chemotherapy (2021) Vol. 53, Iss. 4, pp. 686-686
Open Access | Times Cited: 12
Antiviral potency of long-acting islatravir subdermal implant in SHIV-infected macaques
Fernanda P. Pons‐Faudoa, Nicola Di Trani, Simone Capuani, et al.
Journal of Controlled Release (2023) Vol. 366, pp. 18-27
Open Access | Times Cited: 4
Fernanda P. Pons‐Faudoa, Nicola Di Trani, Simone Capuani, et al.
Journal of Controlled Release (2023) Vol. 366, pp. 18-27
Open Access | Times Cited: 4
Pharmacokinetics of Atorvastatin and Metformin after Coadministration with Islatravir in Healthy Adults
Jacqueline B. McCrea, Munjal Patel, Yang Liu, et al.
The Journal of Clinical Pharmacology (2024)
Open Access | Times Cited: 1
Jacqueline B. McCrea, Munjal Patel, Yang Liu, et al.
The Journal of Clinical Pharmacology (2024)
Open Access | Times Cited: 1
A phase 1, open‐label study to evaluate the drug interaction between islatravir (MK‐8591) and the oral contraceptive levonorgestrel/ethinyl estradiol in healthy adult females
Wendy Ankrom, Deanne Jackson Rudd, Saijuan Zhang, et al.
Journal of the International AIDS Society (2021) Vol. 24, Iss. 12
Open Access | Times Cited: 9
Wendy Ankrom, Deanne Jackson Rudd, Saijuan Zhang, et al.
Journal of the International AIDS Society (2021) Vol. 24, Iss. 12
Open Access | Times Cited: 9
Novel and Investigational HIV Therapies for Treatment and Prevention: Focus on Cabotegravir, Islatravir, and Lenacapavir
Fidelia Bernice, Christin Kilcrease
Current Infectious Disease Reports (2022) Vol. 24, Iss. 7, pp. 89-96
Closed Access | Times Cited: 6
Fidelia Bernice, Christin Kilcrease
Current Infectious Disease Reports (2022) Vol. 24, Iss. 7, pp. 89-96
Closed Access | Times Cited: 6
Evaluating Islatravir Administered Via Microneedle Array Patch for Long-Acting HIV Pre-exposure Prophylaxis Using Physiologically Based Pharmacokinetic Modelling
Hannah Kinvig, Nicolas Cottura, Andrew Lloyd, et al.
European Journal of Drug Metabolism and Pharmacokinetics (2022) Vol. 47, Iss. 6, pp. 855-868
Open Access | Times Cited: 6
Hannah Kinvig, Nicolas Cottura, Andrew Lloyd, et al.
European Journal of Drug Metabolism and Pharmacokinetics (2022) Vol. 47, Iss. 6, pp. 855-868
Open Access | Times Cited: 6
Lack of a Clinically Meaningful Drug Interaction Between the HIV‐1 Antiretroviral Agents Islatravir, Dolutegravir, and Tenofovir Disoproxil Fumarate
Deanne Jackson Rudd, Saijuan Zhang, Kerry L. Fillgrove, et al.
Clinical Pharmacology in Drug Development (2021) Vol. 10, Iss. 12, pp. 1432-1441
Open Access | Times Cited: 7
Deanne Jackson Rudd, Saijuan Zhang, Kerry L. Fillgrove, et al.
Clinical Pharmacology in Drug Development (2021) Vol. 10, Iss. 12, pp. 1432-1441
Open Access | Times Cited: 7
Pharmacokinetic Study of Islatravir and Etonogestrel Implants in Macaques
Michele B. Daly, Andres Wong-Sam, Lingying Li, et al.
Pharmaceutics (2023) Vol. 15, Iss. 12, pp. 2676-2676
Open Access | Times Cited: 2
Michele B. Daly, Andres Wong-Sam, Lingying Li, et al.
Pharmaceutics (2023) Vol. 15, Iss. 12, pp. 2676-2676
Open Access | Times Cited: 2
A Phase 1 Study to Evaluate the Pharmacokinetic Drug‐Drug Interaction Between Islatravir and Methadone in Participants on Stable Methadone Therapy
Randolph P. Matthews, Wendy Ankrom, Whitney Handy, et al.
Clinical Pharmacology in Drug Development (2024) Vol. 14, Iss. 1, pp. 36-43
Open Access
Randolph P. Matthews, Wendy Ankrom, Whitney Handy, et al.
Clinical Pharmacology in Drug Development (2024) Vol. 14, Iss. 1, pp. 36-43
Open Access
Ultra-long-acting refillable nanofluidic implant confers full protection against SHIV infection in non-human primates
Fernanda P. Pons‐Faudoa, Nicola Di Trani, Simone Capuani, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 1
Fernanda P. Pons‐Faudoa, Nicola Di Trani, Simone Capuani, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 1
Intracellular Islatravir-Triphosphate in Dried Blood Spots and Peripheral Blood Mononuclear Cells from Pig-Tailed Macaques
Vincent Mainella, Mary Morrow, Kristina M. Brooks, et al.
AIDS Research and Human Retroviruses (2023) Vol. 40, Iss. 5, pp. 227-230
Closed Access
Vincent Mainella, Mary Morrow, Kristina M. Brooks, et al.
AIDS Research and Human Retroviruses (2023) Vol. 40, Iss. 5, pp. 227-230
Closed Access
Pharmacokinetic and pharmacodynamic features of antiretroviral products
А. N. Useinova, Е. А. Егорова, S. P. Maryanenko, et al.
HIV Infection and Immunosuppressive Disorders (2022) Vol. 14, Iss. 3, pp. 7-23
Open Access
А. N. Useinova, Е. А. Егорова, S. P. Maryanenko, et al.
HIV Infection and Immunosuppressive Disorders (2022) Vol. 14, Iss. 3, pp. 7-23
Open Access
HIV Prevention Utilizing Long-acting Injectables
Eric F. Egelund, Jessica Huston
touchREVIEWS in Infectious Diseases (2022) Vol. 1, Iss. 1, pp. 31-31
Open Access
Eric F. Egelund, Jessica Huston
touchREVIEWS in Infectious Diseases (2022) Vol. 1, Iss. 1, pp. 31-31
Open Access
